Company intelligence / Profile preview
Degranin Therapeutics
Louisville, Kentucky, United Statesdegranin.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Degranin Therapeutics, a University of Louisville spinout, focuses on developing small molecule drugs for life-threatening lung diseases and immune dysregulation. Its lead compound DGN‑23 aims to prevent cytokine storms while preserving neutrophil antimicrobial activity. The company has received SBIR and state matching grants for early-stage development and preclinical testing[1][3][5].
- Therapeutic areas
- PulmonologyImmunology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Louisville academic collaboration/co-development[5]
Beyond the preview
Go deeper on Degranin Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Degranin Therapeutics.